Radivojević, Dragana

Link to this page

Authority KeyName Variants
c85c94f9-7c75-4ad5-a83b-5cd0f9f799da
  • Radivojević, Dragana (7)
Projects

Author's Bibliography

Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach

Golubović, Bojana; Vučićević, Katarina; Radivojević, Dragana; Vezmar-Kovačević, Sandra; Prostran, Milica; Miljković, Branislava

(Društvo medicinskih biohemičara Srbije, Beograd i Versita, 2019)

TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3340
AB  - Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach
VL  - 38
IS  - 3
SP  - 323
EP  - 331
DO  - 10.2478/jomb-2018-0030
ER  - 
@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2019",
abstract = "Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach",
volume = "38",
number = "3",
pages = "323-331",
doi = "10.2478/jomb-2018-0030"
}
Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2019). Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 323-331.
https://doi.org/10.2478/jomb-2018-0030
Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry. 2019;38(3):323-331.
doi:10.2478/jomb-2018-0030 .
Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach" in Journal of Medical Biochemistry, 38, no. 3 (2019):323-331,
https://doi.org/10.2478/jomb-2018-0030 . .
1
8
4
7

Potential drug-drug interactions in kidney transplant patients.

Golubović, Bojana; Drndarević, Aneta; Draganov, Ivana; Radivojević, Dragana; Vezmar-Kovačević, Sandra; Vučićević, Katarina; Prostran, Milica; Miljković, Branislava

(Wiley-Blackwell, Hoboken, 2016)

TY  - CONF
AU  - Golubović, Bojana
AU  - Drndarević, Aneta
AU  - Draganov, Ivana
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2720
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Potential drug-drug interactions in kidney transplant patients.
VL  - 36
IS  - 7
SP  - e96
EP  - e96
DO  - 10.1002/phar.1782
ER  - 
@conference{
author = "Golubović, Bojana and Drndarević, Aneta and Draganov, Ivana and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Prostran, Milica and Miljković, Branislava",
year = "2016",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Potential drug-drug interactions in kidney transplant patients.",
volume = "36",
number = "7",
pages = "e96-e96",
doi = "10.1002/phar.1782"
}
Golubović, B., Drndarević, A., Draganov, I., Radivojević, D., Vezmar-Kovačević, S., Vučićević, K., Prostran, M.,& Miljković, B.. (2016). Potential drug-drug interactions in kidney transplant patients.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 36(7), e96-e96.
https://doi.org/10.1002/phar.1782
Golubović B, Drndarević A, Draganov I, Radivojević D, Vezmar-Kovačević S, Vučićević K, Prostran M, Miljković B. Potential drug-drug interactions in kidney transplant patients.. in Pharmacotherapy. 2016;36(7):e96-e96.
doi:10.1002/phar.1782 .
Golubović, Bojana, Drndarević, Aneta, Draganov, Ivana, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Prostran, Milica, Miljković, Branislava, "Potential drug-drug interactions in kidney transplant patients." in Pharmacotherapy, 36, no. 7 (2016):e96-e96,
https://doi.org/10.1002/phar.1782 . .

Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients

Golubović, Bojana; Prostran, Milica; Miljković, Branislava; Vučićević, Katarina; Radivojević, Dragana; Grabnar, Iztok

(Bentham Science Publ Ltd, Sharjah, 2016)

TY  - JOUR
AU  - Golubović, Bojana
AU  - Prostran, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Grabnar, Iztok
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2678
AB  - Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Medicinal Chemistry
T1  - Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients
VL  - 23
IS  - 19
SP  - 1998
EP  - 2011
DO  - 10.2174/0929867323666151221150214
ER  - 
@article{
author = "Golubović, Bojana and Prostran, Milica and Miljković, Branislava and Vučićević, Katarina and Radivojević, Dragana and Grabnar, Iztok",
year = "2016",
abstract = "Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Medicinal Chemistry",
title = "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients",
volume = "23",
number = "19",
pages = "1998-2011",
doi = "10.2174/0929867323666151221150214"
}
Golubović, B., Prostran, M., Miljković, B., Vučićević, K., Radivojević, D.,& Grabnar, I.. (2016). Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 23(19), 1998-2011.
https://doi.org/10.2174/0929867323666151221150214
Golubović B, Prostran M, Miljković B, Vučićević K, Radivojević D, Grabnar I. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry. 2016;23(19):1998-2011.
doi:10.2174/0929867323666151221150214 .
Golubović, Bojana, Prostran, Milica, Miljković, Branislava, Vučićević, Katarina, Radivojević, Dragana, Grabnar, Iztok, "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients" in Current Medicinal Chemistry, 23, no. 19 (2016):1998-2011,
https://doi.org/10.2174/0929867323666151221150214 . .
10
8
9

Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients

Golubović, Bojana; Vučićević, Katarina; Radivojević, Dragana; Vezmar-Kovačević, Sandra; Prostran, Milica; Miljković, Branislava

(Wiley-Blackwell, Hoboken, 2014)

TY  - CONF
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2199
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients
VL  - 34
IS  - 6
SP  - e114
EP  - e114
DO  - 10.1002/phar.1449
ER  - 
@conference{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients",
volume = "34",
number = "6",
pages = "e114-e114",
doi = "10.1002/phar.1449"
}
Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2014). Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 34(6), e114-e114.
https://doi.org/10.1002/phar.1449
Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients. in Pharmacotherapy. 2014;34(6):e114-e114.
doi:10.1002/phar.1449 .
Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients" in Pharmacotherapy, 34, no. 6 (2014):e114-e114,
https://doi.org/10.1002/phar.1449 . .
2

Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach

Golubović, Bojana; Vučićević, Katarina; Radivojević, Dragana; Vezmar-Kovačević, Sandra; Prostran, Milica; Miljković, Branislava

(Elsevier Science BV, Amsterdam, 2014)

TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2174
AB  - Data from routine therapeutic drug monitoring of 105 adult kidney transplant recipients were used for population pharmacokinetic analysis which was performed using a non-linear mixed-effects modeling. The effect of demographic and clinical factors on tacrolimus clearance was evaluated. Following the initiation of treatment with tacrolimus, the results of our study indicate a decrease of the drug clearance on day 15, 1 and 6 months after transplantation for 4.4%, 6.3% and 10.92%, respectively. Our model suggests a negative correlation between tacrolimus clearance and haematocrit. According to final model, clearance decreases with increasing of aspartate aminotransferase. Our results demonstrated that CL/F increases with patients' weight. This study reveals incensement for 10.4% in tacrolimus clearance with alteration of patients' minimal measured total protein levels to upper normal range. The findings of this study explore various factors of tacrolimus pharmacokinetic variability and point out a relationship between tacrolimus clearance and total plasma protein. Developed model demonstrates the feasibility of estimation of individual tacrolimus clearance and may allow rational individualization of tacrolimus dosing in kidney transplant patients.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach
VL  - 52
SP  - 34
EP  - 40
DO  - 10.1016/j.ejps.2013.10.008
ER  - 
@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2014",
abstract = "Data from routine therapeutic drug monitoring of 105 adult kidney transplant recipients were used for population pharmacokinetic analysis which was performed using a non-linear mixed-effects modeling. The effect of demographic and clinical factors on tacrolimus clearance was evaluated. Following the initiation of treatment with tacrolimus, the results of our study indicate a decrease of the drug clearance on day 15, 1 and 6 months after transplantation for 4.4%, 6.3% and 10.92%, respectively. Our model suggests a negative correlation between tacrolimus clearance and haematocrit. According to final model, clearance decreases with increasing of aspartate aminotransferase. Our results demonstrated that CL/F increases with patients' weight. This study reveals incensement for 10.4% in tacrolimus clearance with alteration of patients' minimal measured total protein levels to upper normal range. The findings of this study explore various factors of tacrolimus pharmacokinetic variability and point out a relationship between tacrolimus clearance and total plasma protein. Developed model demonstrates the feasibility of estimation of individual tacrolimus clearance and may allow rational individualization of tacrolimus dosing in kidney transplant patients.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach",
volume = "52",
pages = "34-40",
doi = "10.1016/j.ejps.2013.10.008"
}
Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2014). Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 52, 34-40.
https://doi.org/10.1016/j.ejps.2013.10.008
Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. in European Journal of Pharmaceutical Sciences. 2014;52:34-40.
doi:10.1016/j.ejps.2013.10.008 .
Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach" in European Journal of Pharmaceutical Sciences, 52 (2014):34-40,
https://doi.org/10.1016/j.ejps.2013.10.008 . .
29
23
31

Potential Influence of Tubular Dysfunction on the Difference Between Estimated and Measured Glomerular Filtration Rate After Kidney Transplantation

Lezaić, V.; Mirković, Duško; Ristić, S.; Radivojević, Dragana; Dajak, Marijana; Naumović, Radomir; Marinković, Jelena; Đukanović, Ljubica

(Elsevier Science Inc, New York, 2013)

TY  - JOUR
AU  - Lezaić, V.
AU  - Mirković, Duško
AU  - Ristić, S.
AU  - Radivojević, Dragana
AU  - Dajak, Marijana
AU  - Naumović, Radomir
AU  - Marinković, Jelena
AU  - Đukanović, Ljubica
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1963
AB  - Purpose. Because no consensus exists regarding the most accurate calculation to estimate glomerular filtration rate (GFR) based on serum creatinine concentrations (sCr) after kidney transplantation, this study sought to assess the potential role of tubular dysfunction on GFR estimates using various equations as well as the effect of pharmacologic blockades on tubular secretion of creatinine on creatinine clearance (ClCr). Methods. Iohexol GFR (mGFR) was performed in 17 stable kidney transplant recipients(R) at >24 months post-transplantation. Their mean age was 48.3 +/- 11.3 years. All R were treated with a calcineurin inhibitor (CNI). At the time of study we measured sCr, 24 hour-ClCr, cystatin C, 24-hour proteinuria, microalbuminuria, FE Na, alfa1-microglobulinuria (alfa1-MG), and CNI concentrations. To block tubular secretion of Cr, recipients were prescribed cimetidine (2400 mg) 2 days before the sCr measurement. Additionally, to exclude dietary influences on sCr, R did not eat meat for 2 days before testing. GFR was estimated using the Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Cockroft-Gault (C&G), and Cystatin C (Cyst C) GFR equations. Mean kidney graft function over the previous 6 months was used as the contra. Pearson correlation was determined between the differences between mGFR and estimatedGFR: Iohexol minus MDRD, EPI, Cyst C or C&G GFR for paired estimates. The diagnostic accuracy of the eGFRs to detect an mGFR of 60 mL/min/1.73 m(2) was examined by receiver operating characteristic curves. Results. Mean mGFR was 75.2 +/- 35.8 mL/min/1.73 m2. The sCr increased but the 24-hour ClCr, MDRD, EPI, and C&G decreased after vs before cimetidine. The difference was significant for sCr (F = 12.933; P = .002) and MDRD GFR (F = 15.750; P = .001). mGFR was not significantly higher than all pair values of eGFRs, and not significantly lower than 24-hour ClCr before and after cimetidine. However, in comparison to all eGFRs, ClCr after cimetidine most approached mGFR. A significant positive correlation was observed between alfa1-MG and the difference between mGFR and MDRD (before, r = .543 [P = .045]; after cimeticline, 0.568 [P = .034]), EPI (before, r = 0.516 [P = .050]; after cimetidine, r = 0.562 [P = .0361), and ClCr (r = 0.633; P = .016), C&G (P = .581; P = .029) before cimetidine. Accuracy of eGFRs to detect mGFR of 60 mL/min/1.73 m(2) showed EPI GFR before cimetidine to show diagnostic accuracy for patients with GFR >60 mL/min/1.73 m(2) with a sensitivity of 81.8% and a specificity of 71.4%.
PB  - Elsevier Science Inc, New York
T2  - Turkish Journal of Medical Sciences
T1  - Potential Influence of Tubular Dysfunction on the Difference Between Estimated and Measured Glomerular Filtration Rate After Kidney Transplantation
VL  - 45
IS  - 4
SP  - 1651
EP  - 1654
DO  - 10.1016/j.transproceed.2013.02.105
ER  - 
@article{
author = "Lezaić, V. and Mirković, Duško and Ristić, S. and Radivojević, Dragana and Dajak, Marijana and Naumović, Radomir and Marinković, Jelena and Đukanović, Ljubica",
year = "2013",
abstract = "Purpose. Because no consensus exists regarding the most accurate calculation to estimate glomerular filtration rate (GFR) based on serum creatinine concentrations (sCr) after kidney transplantation, this study sought to assess the potential role of tubular dysfunction on GFR estimates using various equations as well as the effect of pharmacologic blockades on tubular secretion of creatinine on creatinine clearance (ClCr). Methods. Iohexol GFR (mGFR) was performed in 17 stable kidney transplant recipients(R) at >24 months post-transplantation. Their mean age was 48.3 +/- 11.3 years. All R were treated with a calcineurin inhibitor (CNI). At the time of study we measured sCr, 24 hour-ClCr, cystatin C, 24-hour proteinuria, microalbuminuria, FE Na, alfa1-microglobulinuria (alfa1-MG), and CNI concentrations. To block tubular secretion of Cr, recipients were prescribed cimetidine (2400 mg) 2 days before the sCr measurement. Additionally, to exclude dietary influences on sCr, R did not eat meat for 2 days before testing. GFR was estimated using the Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Cockroft-Gault (C&G), and Cystatin C (Cyst C) GFR equations. Mean kidney graft function over the previous 6 months was used as the contra. Pearson correlation was determined between the differences between mGFR and estimatedGFR: Iohexol minus MDRD, EPI, Cyst C or C&G GFR for paired estimates. The diagnostic accuracy of the eGFRs to detect an mGFR of 60 mL/min/1.73 m(2) was examined by receiver operating characteristic curves. Results. Mean mGFR was 75.2 +/- 35.8 mL/min/1.73 m2. The sCr increased but the 24-hour ClCr, MDRD, EPI, and C&G decreased after vs before cimetidine. The difference was significant for sCr (F = 12.933; P = .002) and MDRD GFR (F = 15.750; P = .001). mGFR was not significantly higher than all pair values of eGFRs, and not significantly lower than 24-hour ClCr before and after cimetidine. However, in comparison to all eGFRs, ClCr after cimetidine most approached mGFR. A significant positive correlation was observed between alfa1-MG and the difference between mGFR and MDRD (before, r = .543 [P = .045]; after cimeticline, 0.568 [P = .034]), EPI (before, r = 0.516 [P = .050]; after cimetidine, r = 0.562 [P = .0361), and ClCr (r = 0.633; P = .016), C&G (P = .581; P = .029) before cimetidine. Accuracy of eGFRs to detect mGFR of 60 mL/min/1.73 m(2) showed EPI GFR before cimetidine to show diagnostic accuracy for patients with GFR >60 mL/min/1.73 m(2) with a sensitivity of 81.8% and a specificity of 71.4%.",
publisher = "Elsevier Science Inc, New York",
journal = "Turkish Journal of Medical Sciences",
title = "Potential Influence of Tubular Dysfunction on the Difference Between Estimated and Measured Glomerular Filtration Rate After Kidney Transplantation",
volume = "45",
number = "4",
pages = "1651-1654",
doi = "10.1016/j.transproceed.2013.02.105"
}
Lezaić, V., Mirković, D., Ristić, S., Radivojević, D., Dajak, M., Naumović, R., Marinković, J.,& Đukanović, L.. (2013). Potential Influence of Tubular Dysfunction on the Difference Between Estimated and Measured Glomerular Filtration Rate After Kidney Transplantation. in Turkish Journal of Medical Sciences
Elsevier Science Inc, New York., 45(4), 1651-1654.
https://doi.org/10.1016/j.transproceed.2013.02.105
Lezaić V, Mirković D, Ristić S, Radivojević D, Dajak M, Naumović R, Marinković J, Đukanović L. Potential Influence of Tubular Dysfunction on the Difference Between Estimated and Measured Glomerular Filtration Rate After Kidney Transplantation. in Turkish Journal of Medical Sciences. 2013;45(4):1651-1654.
doi:10.1016/j.transproceed.2013.02.105 .
Lezaić, V., Mirković, Duško, Ristić, S., Radivojević, Dragana, Dajak, Marijana, Naumović, Radomir, Marinković, Jelena, Đukanović, Ljubica, "Potential Influence of Tubular Dysfunction on the Difference Between Estimated and Measured Glomerular Filtration Rate After Kidney Transplantation" in Turkish Journal of Medical Sciences, 45, no. 4 (2013):1651-1654,
https://doi.org/10.1016/j.transproceed.2013.02.105 . .
3
3
3

Potential Influence of Tubular Dysfunction in Agreement of Estimated and Measured Glomerular Fultration Rate after Kidney Transplantation

Lezaić, V; Mirković, Duško; Ristić, S.; Radivojević, Dragana; Dajak, Marijana; Naumović, Radomir; Đukanović, Ljubica

(Lippincott Williams & Wilkins, Philadelphia, 2012)

TY  - CONF
AU  - Lezaić, V
AU  - Mirković, Duško
AU  - Ristić, S.
AU  - Radivojević, Dragana
AU  - Dajak, Marijana
AU  - Naumović, Radomir
AU  - Đukanović, Ljubica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1658
PB  - Lippincott Williams & Wilkins, Philadelphia
C3  - Transplantation Proceedings
T1  - Potential Influence of Tubular Dysfunction in Agreement of Estimated and Measured Glomerular Fultration Rate after Kidney Transplantation
VL  - 94
IS  - 10
SP  - 873
EP  - 873
DO  - 10.1097/00007890-201211271-01718
ER  - 
@conference{
author = "Lezaić, V and Mirković, Duško and Ristić, S. and Radivojević, Dragana and Dajak, Marijana and Naumović, Radomir and Đukanović, Ljubica",
year = "2012",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Transplantation Proceedings",
title = "Potential Influence of Tubular Dysfunction in Agreement of Estimated and Measured Glomerular Fultration Rate after Kidney Transplantation",
volume = "94",
number = "10",
pages = "873-873",
doi = "10.1097/00007890-201211271-01718"
}
Lezaić, V., Mirković, D., Ristić, S., Radivojević, D., Dajak, M., Naumović, R.,& Đukanović, L.. (2012). Potential Influence of Tubular Dysfunction in Agreement of Estimated and Measured Glomerular Fultration Rate after Kidney Transplantation. in Transplantation Proceedings
Lippincott Williams & Wilkins, Philadelphia., 94(10), 873-873.
https://doi.org/10.1097/00007890-201211271-01718
Lezaić V, Mirković D, Ristić S, Radivojević D, Dajak M, Naumović R, Đukanović L. Potential Influence of Tubular Dysfunction in Agreement of Estimated and Measured Glomerular Fultration Rate after Kidney Transplantation. in Transplantation Proceedings. 2012;94(10):873-873.
doi:10.1097/00007890-201211271-01718 .
Lezaić, V, Mirković, Duško, Ristić, S., Radivojević, Dragana, Dajak, Marijana, Naumović, Radomir, Đukanović, Ljubica, "Potential Influence of Tubular Dysfunction in Agreement of Estimated and Measured Glomerular Fultration Rate after Kidney Transplantation" in Transplantation Proceedings, 94, no. 10 (2012):873-873,
https://doi.org/10.1097/00007890-201211271-01718 . .